Walleye Capital
CYTK icon

Walleye Capital’s Cytokinetics CYTK Stock Holding History

Walleye Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
17,400
+7,200
+71% +$517K 0.01% 1778
2026
Q1 		$672K Sell
10,200
-7,400
-42% -$470K ﹤0.01% 2425
2025
Q4 		$1.12M Sell
17,600
-27,700
-61% -$1.72M ﹤0.01% 2343
2025
Q3 		$2.49M Sell
45,300
-74,200
-62% -$3.06M 0.01% 1413
2025
Q2 		$3.95M Buy
119,500
+118,800
+16,971% +$4.13M 0.02% 1027
2025
Q1 		$28.1K Buy
+700
New +$32.2K ﹤0.01% 3965
2024
Q3 		– Sell
-2,400
Closed -$130K – 5392
2024
Q2 		$130K Sell
2,400
-22,200
-90% -$1.34M ﹤0.01% 4578
2024
Q1 		$1.72M Buy
24,600
+6,300
+34% +$487K ﹤0.01% 2105
2023
Q4 		$1.53M Buy
18,300
+9,300
+103% +$337K ﹤0.01% 1999
2023
Q3 		$265K Sell
9,000
-25,300
-74% -$843K ﹤0.01% 3339
2023
Q2 		$1.12M Buy
+34,300
New +$1.27M ﹤0.01% 1759
2023
Q1 		– Sell
-4,700
Closed -$215K – 4006
2022
Q4 		$215K Buy
4,700
+3,800
+422% +$164K ﹤0.01% 1991
2022
Q3 		$44K Buy
+900
New +$43.3K ﹤0.01% 2609
2020
Q2 		– Sell
-1,000
Closed -$12K – 676
2020
Q1 		$12K Buy
+1,000
New +$12.8K ﹤0.01% 779

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's CYTK Position: Q2 2026 in Review

Walleye Capital opened a new position in Cytokinetics (CYTK) in Q2 2026: 239,728 shares worth $20.4M. The stake represents 0.07% of the portfolio and ranks #243 among its holdings. This is a return to the name: Walleye Capital previously reported a position in CYTK as recently as Q4 2025.

Walleye Capital first reported a position in CYTK in Q2 2019 and has held it in 14 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Walleye Capital held 239,728 shares of Cytokinetics worth $20.4M as of Q2 2026.
  • Cytokinetics was a new Walleye Capital position in Q2 2026.
  • Cytokinetics made up 0.07% of Walleye Capital's portfolio in Q2 2026, its #243 holding.
  • Walleye Capital first reported a position in Cytokinetics in Q2 2019 and has held it in 14 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.